<?xml version="1.0" encoding="UTF-8"?>
<prs:study_collection xmlns:prs="http://clinicaltrials.gov/prs">
  <clinical_study>
    <id_info>
      <provider_name>NLM_DES</provider_name>
      <provider_study_id>S0006HWA</provider_study_id>
      <org_name>AddenbrookesH</org_name>
      <org_study_id>1234</org_study_id>
    </id_info>
    <is_fda_regulated>No</is_fda_regulated>
    <is_section_801>None</is_section_801>
    <delayed_posting>None</delayed_posting>
    <is_ind_study>No</is_ind_study>
    <ind_info>
      <ind_grantor/>
      <ind_number/>
      <ind_serial_number/>
      <has_expanded_access/>
      <expanded_access_nct_id/>
    </ind_info>
    <brief_title>Test Study for my tool</brief_title>
    <acronym>TEST</acronym>
    <official_title>Test Study for my tool</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      </lead_sponsor>
      <resp_party>
        <resp_party_type>Principal Investigator</resp_party_type>
        <investigator_username>djayne</investigator_username>
        <investigator_title>Dr</investigator_title>
        <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
        <name_title/>
        <organization/>
        <phone/>
        <phone_ext/>
        <email/>
      </resp_party>
    </sponsors>
    <oversight_info>
      <irb_info>
        <approval_status>Exempt</approval_status>
      </irb_info>
      <has_dmc>No</has_dmc>
      <fda_regulated_drug>No</fda_regulated_drug>
      <fda_regulated_device>No</fda_regulated_device>
      <post_prior_to_approval>None</post_prior_to_approval>
    </oversight_info>
    <brief_summary>
      <textblock>Test Trial </textblock>
    </brief_summary>
    <detailed_description>
      <textblock/>
    </detailed_description>
    <overall_status>Completed</overall_status>
    <why_stopped/>
    <verification_date>2021-07</verification_date>
    <start_date>2020-01-01</start_date>
    <start_date_type>Actual</start_date_type>
    <end_date/>
    <last_follow_up_date>2021-02-01</last_follow_up_date>
    <last_follow_up_date_type>Actual</last_follow_up_date_type>
    <primary_compl_date>2021-01-01</primary_compl_date>
    <primary_compl_date_type>Actual</primary_compl_date_type>
    <study_design>
      <study_type>Interventional</study_type>
      <interventional_design>
        <interventional_subtype>Treatment</interventional_subtype>
        <phase>Phase 2</phase>
        <assignment>Parallel Assignment</assignment>
        <model_description>
          <textblock/>
        </model_description>
        <allocation>Randomized</allocation>
        <masking/>
        <no_masking>true</no_masking>
        <masked_subject>false</masked_subject>
        <masked_caregiver>false</masked_caregiver>
        <masked_investigator>false</masked_investigator>
        <masked_assessor>false</masked_assessor>
        <masking_description>
          <textblock/>
        </masking_description>
        <control/>
        <number_of_arms>2</number_of_arms>
      </interventional_design>
    </study_design>
    <enrollment>400</enrollment>
    <enrollment_type>Actual</enrollment_type>
    <condition>Vasculitis</condition>
    <arm_group>
      <arm_group_label>Control</arm_group_label>
      <arm_type>No Intervention</arm_type>
      <arm_group_description>
        <textblock/>
      </arm_group_description>
    </arm_group>
    <arm_group>
      <arm_group_label>Ritazarem</arm_group_label>
      <arm_type>Experimental</arm_type>
      <arm_group_description>
        <textblock/>
      </arm_group_description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>ritazarem</intervention_name>
      <intervention_description>
        <textblock>A drug that we want to look at</textblock>
      </intervention_description>
      <arm_group_label>Ritazarem</arm_group_label>
    </intervention>
    <eligibility>
      <study_population>
        <textblock/>
      </study_population>
      <sampling_method/>
      <criteria>
        <textblock>Inclusion Criteria:&#13;
  - Vasculitis&#13;
&#13;
Exclusion Criteria:&#13;
  - </textblock>
      </criteria>
      <healthy_volunteers>No</healthy_volunteers>
      <gender>All</gender>
      <gender_based>No</gender_based>
      <gender_description>
        <textblock/>
      </gender_description>
      <minimum_age>18 Years</minimum_age>
      <maximum_age> N/A</maximum_age>
    </eligibility>
    <overall_contact>
      <first_name>Simon</first_name>
      <middle_name/>
      <last_name>Bond</last_name>
      <degrees/>
      <phone>+441223596475</phone>
      <phone_ext/>
      <email>simon.bond@addenbrookes.nhs.uk</email>
    </overall_contact>
    <overall_contact_backup>
      <first_name/>
      <middle_name/>
      <last_name/>
      <degrees/>
      <phone/>
      <phone_ext/>
      <email/>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Cambridge Clinical Trials Unit</name>
        <address>
          <city>Cambridge</city>
          <state/>
          <country>United Kingdom</country>
          <zip>cb20qq</zip>
        </address>
      </facility>
      <status>Completed</status>
      <contact>
        <first_name>Simon</first_name>
        <middle_name/>
        <last_name>Bond</last_name>
        <degrees/>
        <phone>01223596475</phone>
        <phone_ext/>
        <email>simon.bond@addenbrookes.nhs.uk</email>
      </contact>
      <contact_backup>
        <first_name/>
        <middle_name/>
        <last_name/>
        <degrees/>
        <phone/>
        <phone_ext/>
        <email/>
      </contact_backup>
    </location>
    <ipd_sharing_statement>
      <sharing_ipd>No</sharing_ipd>
      <ipd_description>
        <textblock/>
      </ipd_description>
      <ipd_info_type_protocol>false</ipd_info_type_protocol>
      <ipd_info_type_sap>false</ipd_info_type_sap>
      <ipd_info_type_icf>false</ipd_info_type_icf>
      <ipd_info_type_csr>false</ipd_info_type_csr>
      <ipd_info_type_analytic_code>false</ipd_info_type_analytic_code>
      <ipd_time_frame>
        <textblock/>
      </ipd_time_frame>
      <ipd_access_criteria>
        <textblock/>
      </ipd_access_criteria>
      <ipd_url>http://</ipd_url>
    </ipd_sharing_statement>
    <rrs:result xmlns:rrs="http://clinicaltrials.gov/rrs">
      <certainAgreement/>
      <outcomeMeasures>
        <outcomeMeasure>
          <measureRows/>
          <measureDescription/>
          <timeFrame/>
          <title>Time to relapse</title>
          <anticipatedResultPostingDate/>
          <measureType>Primary</measureType>
          <outcomeMeasureAnalyses/>
          <outcomeReportingGroups/>
        </outcomeMeasure>
      </outcomeMeasures>
      <pointOfContact/>
      <reportedEvents>
        <allCauseMortComment>all-cause mortality</allCauseMortComment>
        <assessmentType>Non-Systematic Assessment</assessmentType>
        <frequencyReportingThreshold>0.0</frequencyReportingThreshold>
        <frequentAdverseEvents>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>13</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Abdominal distension</notes>
            <organSystemName>Gastrointestinal disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Abdominal distension</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>4</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Abdominal infection</notes>
            <organSystemName>Infections and infestations</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Abdominal infection</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>9</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Abdominal soft tissue necrosis</notes>
            <organSystemName>Musculoskeletal and connective tissue disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Abdominal soft tissue necrosis</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>17</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>18</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Abducens nerve disorder</notes>
            <organSystemName>Nervous system disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Abducens nerve disorder</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>18</numEvents>
                <numSubjectsAffected>11</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Acidosis</notes>
            <organSystemName>Metabolism and nutrition disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Acidosis</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Activated partial thromboplastin time prolonged</notes>
            <organSystemName>Investigations</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Activated partial thromboplastin time prolonged</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>15</numEvents>
                <numSubjectsAffected>11</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Acute coronary syndrome</notes>
            <organSystemName>Cardiac disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Acute coronary syndrome</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>21</numEvents>
                <numSubjectsAffected>11</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Acute kidney injury</notes>
            <organSystemName>Renal and urinary disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Acute kidney injury</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>18</numEvents>
                <numSubjectsAffected>10</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>4</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Adrenal insufficiency</notes>
            <organSystemName>Endocrine disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Adrenal insufficiency</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Adult respiratory distress syndrome</notes>
            <organSystemName>Respiratory, thoracic and mediastinal disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Adult respiratory distress syndrome</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Agitation</notes>
            <organSystemName>Psychiatric disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Agitation</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>17</numEvents>
                <numSubjectsAffected>9</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Allergic reaction</notes>
            <organSystemName>Immune system disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Allergic reaction</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>15</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Alopecia</notes>
            <organSystemName>Skin and subcutaneous tissue disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Alopecia</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Anemia</notes>
            <organSystemName>Blood and lymphatic system disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Anemia</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>17</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Ankle fracture</notes>
            <organSystemName>Injury, poisoning and procedural complications</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Ankle fracture</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>15</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Azoospermia</notes>
            <organSystemName>Reproductive system and breast disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Azoospermia</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Bile duct stenosis</notes>
            <organSystemName>Hepatobiliary disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Bile duct stenosis</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Blurred vision</notes>
            <organSystemName>Eye disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Blurred vision</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Capillary leak syndrome</notes>
            <organSystemName>Vascular disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Capillary leak syndrome</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>15</numEvents>
                <numSubjectsAffected>10</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Chills</notes>
            <organSystemName>General disorders and administration site conditions</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Chills</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>4</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Congenital, familial and genetic disorders - Other, specify</notes>
            <organSystemName>Congenital, familial and genetic disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Congenital, familial and genetic disorders - Other, specify</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>18</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Ear pain</notes>
            <organSystemName>Ear and labyrinth disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Ear pain</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>22</numEvents>
                <numSubjectsAffected>14</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Fetal death</notes>
            <organSystemName>Pregnancy, puerperium and perinatal conditions</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Fetal death</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>13</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Leukemia secondary to oncology chemotherapy</notes>
            <organSystemName>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Leukemia secondary to oncology chemotherapy</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>3</numEvents>
                <numSubjectsAffected>1</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Menopause</notes>
            <organSystemName>Social circumstances</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Menopause</term>
          </frequentEvent>
          <frequentEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>15</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Surgical and medical procedures - Other, specify</notes>
            <organSystemName>Surgical and medical procedures</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Surgical and medical procedures - Other, specify</term>
          </frequentEvent>
        </frequentAdverseEvents>
        <interventionGroups>
          <interventionGroup id="ReportedEvents-InterventionGroup.1">
            <description>Group A</description>
            <numDeaths>3</numDeaths>
            <numSubjectsFrequentEvents>10</numSubjectsFrequentEvents>
            <numSubjectsSeriousEvents>10</numSubjectsSeriousEvents>
            <partAtRiskAllCauseMort>20</partAtRiskAllCauseMort>
            <partAtRiskFrequentEvents>20</partAtRiskFrequentEvents>
            <partAtRiskSeriousEvents>20</partAtRiskSeriousEvents>
            <title>Group A</title>
          </interventionGroup>
          <interventionGroup id="ReportedEvents-InterventionGroup.2">
            <description>Group B</description>
            <numDeaths>6</numDeaths>
            <numSubjectsFrequentEvents>14</numSubjectsFrequentEvents>
            <numSubjectsSeriousEvents>13</numSubjectsSeriousEvents>
            <partAtRiskAllCauseMort>22</partAtRiskAllCauseMort>
            <partAtRiskFrequentEvents>22</partAtRiskFrequentEvents>
            <partAtRiskSeriousEvents>22</partAtRiskSeriousEvents>
            <title>Group B</title>
          </interventionGroup>
          <interventionGroup id="ReportedEvents-InterventionGroup.3">
            <description>Group C</description>
            <numDeaths>2</numDeaths>
            <numSubjectsFrequentEvents>11</numSubjectsFrequentEvents>
            <numSubjectsSeriousEvents>9</numSubjectsSeriousEvents>
            <partAtRiskAllCauseMort>18</partAtRiskAllCauseMort>
            <partAtRiskFrequentEvents>18</partAtRiskFrequentEvents>
            <partAtRiskSeriousEvents>18</partAtRiskSeriousEvents>
            <title>Group C</title>
          </interventionGroup>
        </interventionGroups>
        <notes/>
        <seriousAdverseEvents>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>4</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Abdominal distension</notes>
            <organSystemName>Gastrointestinal disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Abdominal distension</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Abdominal infection</notes>
            <organSystemName>Infections and infestations</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Abdominal infection</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Abdominal soft tissue necrosis</notes>
            <organSystemName>Musculoskeletal and connective tissue disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Abdominal soft tissue necrosis</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Abducens nerve disorder</notes>
            <organSystemName>Nervous system disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Abducens nerve disorder</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>15</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Acidosis</notes>
            <organSystemName>Metabolism and nutrition disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Acidosis</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Activated partial thromboplastin time prolonged</notes>
            <organSystemName>Investigations</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Activated partial thromboplastin time prolonged</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>4</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>15</numEvents>
                <numSubjectsAffected>9</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Acute coronary syndrome</notes>
            <organSystemName>Cardiac disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Acute coronary syndrome</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>0</numEvents>
                <numSubjectsAffected>0</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Acute kidney injury</notes>
            <organSystemName>Renal and urinary disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Acute kidney injury</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>17</numEvents>
                <numSubjectsAffected>12</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Adrenal insufficiency</notes>
            <organSystemName>Endocrine disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Adrenal insufficiency</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>17</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>22</numEvents>
                <numSubjectsAffected>12</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Adult respiratory distress syndrome</notes>
            <organSystemName>Respiratory, thoracic and mediastinal disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Adult respiratory distress syndrome</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>15</numEvents>
                <numSubjectsAffected>10</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Agitation</notes>
            <organSystemName>Psychiatric disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Agitation</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>13</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Allergic reaction</notes>
            <organSystemName>Immune system disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Allergic reaction</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>3</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Alopecia</notes>
            <organSystemName>Skin and subcutaneous tissue disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Alopecia</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>13</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Anemia</notes>
            <organSystemName>Blood and lymphatic system disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Anemia</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Ankle fracture</notes>
            <organSystemName>Injury, poisoning and procedural complications</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Ankle fracture</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Azoospermia</notes>
            <organSystemName>Reproductive system and breast disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Azoospermia</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>9</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>1</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Bile duct stenosis</notes>
            <organSystemName>Hepatobiliary disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Bile duct stenosis</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Blurred vision</notes>
            <organSystemName>Eye disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Blurred vision</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>9</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Capillary leak syndrome</notes>
            <organSystemName>Vascular disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Capillary leak syndrome</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>20</numEvents>
                <numSubjectsAffected>10</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>17</numEvents>
                <numSubjectsAffected>7</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Chills</notes>
            <organSystemName>General disorders and administration site conditions</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Chills</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>11</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>9</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Congenital, familial and genetic disorders - Other, specify</notes>
            <organSystemName>Congenital, familial and genetic disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Congenital, familial and genetic disorders - Other, specify</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>2</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>9</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>10</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Ear pain</notes>
            <organSystemName>Ear and labyrinth disorders</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Ear pain</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>14</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Fetal death</notes>
            <organSystemName>Pregnancy, puerperium and perinatal conditions</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Fetal death</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>8</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>4</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Leukemia secondary to oncology chemotherapy</notes>
            <organSystemName>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Leukemia secondary to oncology chemotherapy</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>8</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>12</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>6</numEvents>
                <numSubjectsAffected>6</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Menopause</notes>
            <organSystemName>Social circumstances</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Menopause</term>
          </seriousEvent>
          <seriousEvent>
            <adverseEventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.1</reportingGroupId>
                <numEvents>5</numEvents>
                <numSubjectsAffected>5</numSubjectsAffected>
                <numSubjects>20</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.2</reportingGroupId>
                <numEvents>16</numEvents>
                <numSubjectsAffected>9</numSubjectsAffected>
                <numSubjects>22</numSubjects>
              </eventStats>
              <eventStats>
                <reportingGroupId>ReportedEvents-InterventionGroup.3</reportingGroupId>
                <numEvents>7</numEvents>
                <numSubjectsAffected>3</numSubjectsAffected>
                <numSubjects>18</numSubjects>
              </eventStats>
            </adverseEventStats>
            <assessmentType>Non-Systematic Assessment</assessmentType>
            <notes>Surgical and medical procedures - Other, specify</notes>
            <organSystemName>Surgical and medical procedures</organSystemName>
            <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
            <term>Surgical and medical procedures - Other, specify</term>
          </seriousEvent>
        </seriousAdverseEvents>
        <sourceVocabulary>MedDRA 22.0</sourceVocabulary>
        <timeFrame>Timeframe for AE</timeFrame>
      </reportedEvents>
    </rrs:result>
  </clinical_study>
</prs:study_collection>
